Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Bristol-Myers’ 2013 Payments to Health Professionals Total 4.9 Billion Yen
September 18, 2014
- Eisai Inks Two Joint Research Deals for Novel Antimalarial Agents
September 18, 2014
- Kaketsuken Wins Grants for Dengue Vaccine Program from GHIT Fund
September 18, 2014
- Eli Lilly, AstraZeneca to Codevelop BACE Inhibitor for AD Treatment
September 18, 2014
- Shionogi Slapped with 1.3 Billion Yen in Back Taxes over ViiV Deal
September 17, 2014
- Novartis Files Jakavi for Polycythemia Vera in Japan
September 17, 2014
- Nippon Shinyaku to Gear Up R&D, Commercialization of Nucleic Acid Products
September 17, 2014
- Takeda Picks Teva’s Gerard Greco as Global Quality Officer
September 17, 2014
- Sanofi Taps Call Center to Prevent Patient Dropouts from Insulin Therapy
September 16, 2014
- Pharmacy Chains Hurrying to Reach Price Settlements with Wholesalers ahead of Sept.-End Deadline
September 16, 2014
- Novartis Pharma Paid 22.9 Billion Yen to Healthcare Professionals in 2013
September 16, 2014
- AstraZeneca’s 2013 Payments to Healthcare Professionals Reach 7.5 Billion Yen
September 16, 2014
- JB, MTPC to Cease Sales Collaboration for Plasma Products in March 2015
September 16, 2014
- Takara Bio Pushes for Melanoma Drug Development with Eye on Fast Approval
September 12, 2014
- Shionogi Paid 15.2 Billion Yen to Medical Institutions in FY2013
September 12, 2014
- LEO Pharma Launches Its 1st Product in Japan, with Kyowa Kirin as Distributor
September 12, 2014
- Nobelpharma Collaborates with US Research Institute for Development of Endometriosis Treatment
September 12, 2014
- US FDA Approves Xtandi for Chemotherapy-Naïve Patients with Metastatic CRPC: Astellas
September 12, 2014
- Sawai to Comarket Sandoz’s Filgrastim Biosimilar
September 11, 2014
- Eisai Partners with Kyorin for Utilization of Eisai's Compound Library in Antibacterial Field
September 11, 2014
ページ
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…